Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Coronavirus Pandemic Expected to Significantly Disrupt Hologic Q2 Revenues

Coronavirus Pandemic Expected to Significantly Disrupt Hologic Q2 Revenues

Apr 07, 2020
|
staff reporter

NEW YORK – Citing the effects of the coronavirus pandemic, Hologic said Tuesday that it expects to report total revenues of $756.1 million for its fiscal second quarter, down 8 percent from $818.4 million in Q2 2019.

The firm also withdrew its 2020 financial guidance due to the uncertain economic impact on its business of the COVID-19 pandemic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Lots of Voided Tests

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Score Disparities Found

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

Maybe an RNA-DNA World

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

Nature Papers Describe Sequencing of Sperm Genomes, Approach to Detect Residual Cancer, More

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

What's Popular?

In Molecular Diagnostics

  1. Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck Cancer

  2. FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

  3. Guardant Health Prices $315M Public Offering

  4. Ravgen Sues Natera Over Cell-Free DNA Genetic Testing Patents

  5. CDC Develops Test for Simultaneous Detection of COVID-19, Flu

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.